Is Nexalin Technology Inc (NXL) Stock a Good Buy for Short-term Investors?

At the time of writing, Nexalin Technology Inc [NXL] stock is trading at $3.72, up 1.09%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NXL shares have gain 27.40% over the last week, with a monthly amount glided 16.61%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

For the past year, the stock price of Nexalin Technology Inc fluctuated between $0.25 and $4.49. Nexalin Technology Inc [NASDAQ: NXL] shares were valued at $3.72 at the most recent close of the market.

Analyzing the NXL fundamentals

According to Nexalin Technology Inc [NASDAQ:NXL], the company’s sales were 0.16M for trailing twelve months, which represents an 49.43% jump. Gross Profit Margin for this corporation currently stands at -5.73% with Operating Profit Margin at -40.13%, Pretax Profit Margin comes in at -34.27%, and Net Profit Margin reading is -34.27%. To continue investigating profitability, this company’s Return on Assets is posted at -1.06, Equity is -1.88 and Total Capital is -1.31.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.49 points at the first support level, and at 3.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.87, and for the 2nd resistance point, it is at 4.03.

Ratios To Look Out For

It is important to note that Nexalin Technology Inc [NASDAQ:NXL] has a current ratio of 16.39. As well, the Quick Ratio is 15.86, while the Cash Ratio is 0.27. Considering the valuation of this stock, the price to sales ratio is 309.31, the price to book ratio is 9.65.

Transactions by insiders

Recent insider trading involved Owens David, Chief Medical Officer, that happened on Feb 04 ’25 when 1000.0 shares were purchased. Chief Medical Officer, Owens David completed a deal on Feb 04 ’25 to buy 1000.0 shares. Meanwhile, Chief Medical Officer Owens David bought 1500.0 shares on Jan 28 ’25.

Related Posts